NASDAQ:KLDO - Kaleido Biosciences Stock Price, News & Analysis

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

Kaleido Biosciences Inc (NASDAQ:KLDO) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.09. View Kaleido Biosciences' Earnings History.

Kaleido Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Kaleido Biosciences.

5 brokerages have issued twelve-month price targets for Kaleido Biosciences' stock. Their predictions range from $15.00 to $20.00. On average, they anticipate Kaleido Biosciences' stock price to reach $17.70 in the next year. This suggests a possible upside of 95.1% from the stock's current price. View Analyst Price Targets for Kaleido Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kaleido Biosciences.

Media stories about KLDO stock have trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kaleido Biosciences earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Kaleido Biosciences.

Kaleido Biosciences saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 741,200 shares, an increase of 9.9% from the June 30th total of 674,300 shares. Based on an average trading volume of 59,100 shares, the short-interest ratio is presently 12.5 days. Currently, 8.4% of the company's stock are short sold. View Kaleido Biosciences' Current Options Chain.

Some companies that are related to Kaleido Biosciences include Varex Imaging (VREX), Omeros (OMER), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), CareDx (CDNA), Accelerate Diagnostics (AXDX), Axonics Modulation Technologies (AXNX), Dicerna Pharmaceuticals (DRNA), Cryolife (CRY), NanoString Technologies (NSTG), Orthofix Medical (OFIX), Nextgen Healthcare (NXGN), Twist Bioscience (TWST), Tactile Systems Technology (TCMD) and Y-mAbs Therapeutics (YMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Micron Technology (MU), NVIDIA (NVDA), Sequential Brands Group (SQBG), TG Therapeutics (TGTX), Cross Timbers Royalty Trust (CRT), Cara Therapeutics (CARA), HEXO (HEXO), Intel (INTC), JD.Com (JD) and Prospect Capital (PSEC).

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Kaleido Biosciences' lock-up period expires on Tuesday, August 27th. Kaleido Biosciences had issued 5,000,000 shares in its IPO on February 28th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. After the expiration of Kaleido Biosciences' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Kaleido Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artal Group S.A. (3.02%), BlackRock Inc. (0.82%), Vanguard Group Inc. (0.31%), Victory Capital Management Inc. (0.30%), Charles Schwab Investment Management Inc. (0.10%) and Menta Capital LLC (0.05%). Company insiders that own Kaleido Biosciences stock include Michael W Bonney and Ventures Fund V LP Flagship. View Institutional Ownership Trends for Kaleido Biosciences.

KLDO stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A. and Victory Capital Management Inc.. View Insider Buying and Selling for Kaleido Biosciences.

KLDO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Charles Schwab Investment Management Inc., Menta Capital LLC, Northern Trust Corp and Tower Research Capital LLC TRC . Company insiders that have bought Kaleido Biosciences stock in the last two years include Michael W Bonney and Ventures Fund V LP Flagship. View Insider Buying and Selling for Kaleido Biosciences.

Shares of KLDO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of KLDO stock can currently be purchased for approximately $9.07.

Kaleido Biosciences has a market capitalization of $270.59 million. Kaleido Biosciences employs 118 workers across the globe.View Additional Information About Kaleido Biosciences.